Biotechnology company 3Helix, Inc. ("3Helix") announced today that it has received over 1.4 Million US Dollars of a Phase II Small Business Innovation Research (SIBR) grant from the National Institutes of Health (NIH) to develop its proprietary Collagen Hybridizing Peptide agent for detecting damaged collagen in histological and pre-clinical studies. This two-year project, funded by the Office of Research Infrastructure Programs (ORIP) of NIH, will allow 3Helix to perform studies to develop and validate the first-of-its-kind near infrared fluorescence peptide research product for assessing collagen damage by live imaging in various animal disease models. This SBIR grant, together with a previous SBIR grant and private investments received in 2016, brings 3Helix's seed fund level to $2M.

With successful completion of the project, 3Helix will open new avenues for basic biomedical research, pre-clinical drug development, and potentially new clinical diagnosis of a variety of critical disease areas, including cancer, arthritis, cardiovascular disease, and fibrosis.

About 3Helix: 3Helix has developed a series of proprietary Collagen Hybridizing Peptide (CHP) research products that directly target the damaged collagen molecule. Collagen is the major component of nearly every human tissue. Damage to collagen is a strong indication of a variety of diseases involving inflammation and abnormal tissue remodeling, such as myocardial infarction, arthritis, skin aging, and fibrosis. Beyond providing CHP as a research tool for laboratory use in academia and industry, 3Helix is advancing its compounds to enable superior diagnosis and novel treatment of human conditions.

3Helix is based in Salt Lake City, Utah. It was founded in 2015 by Drs. Yang Li and Michael Yu based on the technology that they invented at the Johns Hopkins University.

Leave a Reply

Please wait...

Subscribe to our newsletter

Want to be notified when our article is published? Enter your email address and name below to be the first to know!